Neogenomics started Overweight at Stephens

"The company is poised to continue its recent robust growth trends via share gains, menu expansion, increased direct sales efforts, and potential M&A activity," says analyst Drew Jones, initiating Neogenomics (NEO +1.1%) with a Buy and $6 price target. "Additionally, NEO will also begin to show meaningful penetration of the CRO opportunity (to date, 5% of revenues) through its new relationship with Covance."

"Management has proved its mettle," he adds, noting NEO is the rare company to have had multiple 5% negative revenue hits yet still continue to show top-line growth and margin expansion.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs